Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06349512 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)

Study acronym: FAP-IT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 27 words
    • Site details revised at 3 of 6 sites
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Primary and study completion dates: Nov 30, 2027 to Nov 30, 2032
    • Secondary endpoints: 4 to 5
    • Site details revised at 6 of 6 sites
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 15, 2024 to Oct 14, 2024
    • Study sites: 0 to 6
    • Primary and study completion dates: Jul 30, 2027 to Nov 30, 2027
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC.
Trial Details
NCT Number NCT06349512
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Triple Negative Breast Cancer
Related terms Triple Negative Breast Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov